The Court of Justice of the European Union (CJEU) issued a judgment in a case concerning the “deductive method” under Article 30(2)(b) of the Community Customs Code in the special context of the customs valuation of the imported medicines.
The CJEU addressed what is meant by the term “similar goods” and the implications of discounts on the price when applying the deductive method of customs valuation.
The case is: Oribalt Rīga (C-1/18)
The Community Customs Code has now been replaced by the Union Customs Code; however, the rules governing the deductive valuation method are still effective and are almost identical in wording to the former rules.
A company in Latvia and an Indian company entered into a consignment agreement, under which the Latvian company imported goods (medicines) into Latvia for free circulation in the European Union.
An inspection by the Latvian customs authorities (VID) ultimately led to questions about the deductive method of customs valuation being referred to the CJEU.
The first question addressed to the CJEU concerned which factors are to be taken into account when choosing appropriate “similar goods” in applying the deductive method of customs valuation under Article 30(2)(b) Customs Code to medicines. This question was of central importance in this case because the customs authorities asserted that the imported goods could not be valued on the basis of deductive method since the VID lacked the necessary knowledge and information to assess whether medicines produced by other sellers were in fact similar to the goods produced by the Indian company.
The CJEU noted that the definition of “similar goods” was broad and was based on a factual assessment that allows for a broad application to all types of goods—including medicines. In order to identify the similar goods, the customs authorities must use all data available to determine the customs value as accurately and faithfully as possible. According to the CJEU, the composition of the medicines, the substitutability of their functions, and their commercially interchangeability were factors to be considered in determining whether goods are similar. For purposes of the factual assessment, all the elements of such goods that may affect their economic value, such as the market position of the imported goods and of its producer, must be considered.
90-day time limit
The second question referred to the CJEU was whether the time limit of 90 days as a reference period for similar goods (pursuant to Article 152(1) of the implementing regulation) may be applied flexibly so as to allow “more similar” goods imported beyond a period of 90 days to be considered.
The CJEU concluded that the time limit of 90 days referred to in Article 152(1)(b) was an exception to the principle that the customs value reflects the real economic value of the goods at or about the time the goods valued enter the EU. For this reason, the period of 90 days was found to represent a strict limit when the customs value is determined using the deductive method.
The CJEU was asked to address whether the discounts granted (that determined the price at which the imported goods were in fact sold) were to be taken into account when determining the customs value in accordance with Article 30(2)(c). Here, the CJEU answered in the negative and held that commercial discounts cannot be taken into account when the customs value is determined using the deductive method. The CJEU took into consideration, inter alia, the fact that if commercial discounts were to be taken into account, this would lead to a customs value that would be further removed from the real economic value of the imported goods being valued.
Read a June 2019 report prepared by the KPMG member firm in the Netherlands
The KPMG logo and name are trademarks of KPMG International. KPMG International is a Swiss cooperative that serves as a coordinating entity for a network of independent member firms. KPMG International provides no audit or other client services. Such services are provided solely by member firms in their respective geographic areas. KPMG International and its member firms are legally distinct and separate entities. They are not and nothing contained herein shall be construed to place these entities in the relationship of parents, subsidiaries, agents, partners, or joint venturers. No member firm has any authority (actual, apparent, implied or otherwise) to obligate or bind KPMG International or any member firm in any manner whatsoever. The information contained in herein is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavor to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act on such information without appropriate professional advice after a thorough examination of the particular situation. For more information, contact KPMG's Federal Tax Legislative and Regulatory Services Group at: + 1 202 533 4366, 1801 K Street NW, Washington, DC 20006.